Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Rubius Therapeutics, Inc.
  6. Summary
    RUBY   US78116T1034

RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
26.86(c) 26.79(c) 26.34(c) 27.6(c) 28.43(c) Last
311 707 403 667 303 362 370 345 723 491 Volume
+1.74% -0.26% -1.68% +4.78% +3.01% Change
More quotes
Financials (USD)
Sales 2021 - - -
Net income 2021 -185 M - -
Net cash position 2021 119 M - -
P/E ratio 2021 -13,3x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -210 M - -
Net cash position 2022 167 M - -
P/E ratio 2022 -12,9x
Yield 2022 -
Capitalization 2 465 M 2 465 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 231
Free-Float 93,3%
More Financials
Company
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune... 
Read more
More about the company
Ratings of Rubius Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about RUBIUS THERAPEUTICS, INC.
05/20Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
GL
05/19Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clini..
GL
05/18RUBIUS THERAPEUTICS  : Morgan Stanley Adjusts Rubius Therapeutics' Price Target ..
MT
05/13RUBIUS THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holders..
AQ
05/12RUBIUS THERAPEUTICS  : Announces Publication of RTX-321 Preclinical Data in Natu..
AQ
05/12RUBIUS THERAPEUTICS  : Continued Progress in Advancing Clinical Programs with Fu..
PU
05/10RUBIUS THERAPEUTICS  : Posts Narrower Q1 Loss
MT
05/10RUBIUS THERAPEUTICS  : Management's Discussion and Analysis of Financial Conditi..
AQ
05/10RUBIUS THERAPEUTICS, INC.  : Results of Operations and Financial Condition, Fina..
AQ
05/10RUBIUS THERAPEUTICS  : Reports First Quarter 2021 Financial Results and Provides..
AQ
04/26Rubius Therapeutics to Announce First Quarter 2021 Financial Results
GL
04/12RUBIUS THERAPEUTICS  : Begins Phase 1 Clinical Trial of RTX-321 to Treat HPV 16-..
MT
04/12Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial o..
GL
04/09Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase ..
GL
03/24RUBIUS THERAPEUTICS  : RUBY) sees Significant Insider buy Reversing Trend of Sel..
MT
More news
News in other languages on RUBIUS THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
More recommendations
Chart RUBIUS THERAPEUTICS, INC.
Duration : Period :
Rubius Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 30,17 $
Last Close Price 28,43 $
Spread / Highest target 40,7%
Spread / Average Target 6,11%
Spread / Lowest Target -29,7%
EPS Revisions
Managers and Directors
NameTitle
Pablo J. Cagnoni President, Chief Executive Officer & Director
Jose Carmona Treasurer, Chief Financial & Accounting Officer
David R. Epstein Executive Chairman
Spencer Fisk Senior Vice President-Technical Operations
Christina Coughlin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RUBIUS THERAPEUTICS, INC.274.57%2 465
GILEAD SCIENCES, INC.16.98%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE170.58%57 615
REGENERON PHARMACEUTICALS9.45%54 424
VERTEX PHARMACEUTICALS-17.58%49 966